Sumitomo Mitsui Trust Group Inc. Acquires 332,505 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Sumitomo Mitsui Trust Group increased its stake in IQVIA by 41.6%, buying 332,505 shares to own 1,132,072 shares (about 0.66% of the company) worth roughly $255.18 million.
• IQVIA topped quarterly expectations with $3.42 EPS and revenue up 10.3% year‑over‑year, and set FY2026 guidance of 12.55–12.85 EPS.
• Analysts carry an overall "Buy" consensus with a $226.63 average target, though price targets vary and the stock trades near $167.49, below its 200‑day average of $204.31.

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,132,072 shares of the medical research company's stock after buying an additional 332,505 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.66% of IQVIA worth $255,180,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Robeco Institutional Asset Management B.V. boosted its holdings in shares of IQVIA by 3.1% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 181,263 shares of the medical research company's stock worth $40,858,000 after buying an additional 5,389 shares in the last quarter. Coerente Capital Management bought a new position in shares of IQVIA in the 4th quarter worth $277,000. Telos Capital Management Inc. lifted its holdings in shares of IQVIA by 0.3% in the 4th quarter. Telos Capital Management Inc. now owns 44,216 shares of the medical research company's stock worth $9,967,000 after purchasing an additional 125 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of IQVIA by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 226,646 shares of the medical research company's stock worth $51,088,000 after purchasing an additional 27,510 shares in the last quarter. Finally, Premier Path Wealth Partners LLC bought a new position in shares of IQVIA in the 4th quarter worth $338,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IQV shares. TD Cowen upgraded IQVIA from a "hold" rating to a "buy" rating and increased their target price for the stock from $174.00 to $213.00 in a report on Monday, March 9th. UBS Group cut their target price on IQVIA from $280.00 to $240.00 and set a "buy" rating on the stock in a report on Friday, February 6th. Truist Financial cut their target price on IQVIA from $290.00 to $245.00 and set a "buy" rating on the stock in a report on Thursday, February 19th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Morgan Stanley set a $240.00 price objective on IQVIA in a research note on Wednesday, February 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $226.63.

IQVIA Price Performance

Shares of NYSE:IQV opened at $167.49 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock's fifty day simple moving average is $173.38 and its two-hundred day simple moving average is $204.31. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The stock has a market cap of $28.42 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.62 and a beta of 1.39.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analysts' expectations of $4.24 billion. During the same period last year, the business earned $3.12 EPS. The business's revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.